← Leaderboards
Douglas Eugene Vaughan
Vanderbilt University
$19,799,621
Attributed
$19,799,621
Total exposure
22
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,392,172 · 24
By mechanism
R01$13,563,231 · 4
P01$8,803,490 · 2
P50$3,170,311 · 1
R35$2,212,020 · 1
T32$1,899,448 · 1
U24$776,793 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Carl Hirschie Johnson$20,522,718
- John Atlas Phillips III$14,651,319
Others in their field
Top investigators on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Judith S Hochman · New York University School Of Medicine$110,228,771
Research focus
Cardiovascular SystemCardiovascular DiseasesPlasminogen Activator Inhibitor 1DesignPlasminogen Activator InhibitorsProgramsFibrinolysisBlood VesselsMolecularClinical ResearchHuman SubjectRegulationThrombosisCellsAgingLaboratoriesPhenotypeBaseResponseFunctional DisorderAnimalsAngiotensin IiPreventCardiac
Grant awards (87)
Heterozygous SERPINE1 Deficiency Confers Durable Cardiovascular Fitness in Humans$1,098,010
R35 · FY2025 · HL · contact PI
Heterozygous SERPINE1 Deficiency Confers Durable Cardiovascular Fitness in Humans$1,114,010
R35 · FY2024 · HL · contact PI
Pleiotropic Role of PAI-1 in Cardiovascular Aging$712,074
R01 · FY2023 · HL · contact PI
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology$670,792
R01 · FY2022 · HL · contact PI
Evolutionary Advantage of Heterozygous PAI-1 Deficiency in Humans$300,000
R56 · FY2022 · AG · contact PI
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology$671,120
R01 · FY2021 · HL · contact PI
PAI-1 and Vascular Senescence$546,166
R01 · FY2021 · HL · contact PI
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology$671,438
R01 · FY2020 · HL · contact PI
PAI-1 and Vascular Senescence$546,166
R01 · FY2020 · HL · contact PI
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology$553,789
R01 · FY2019 · HL · contact PI
PAI-1 and Vascular Senescence$546,166
R01 · FY2019 · HL · contact PI
PAI-1 and Vascular Senescence$652,573
R01 · FY2018 · HL · contact PI
PAI-1 & Vascular Senescence$364,144
R01 · FY2017 · HL · contact PI
PAI-1 & Vascular Senescence$360,259
R01 · FY2016 · HL · contact PI
PAI-1 & Vascular Senescence$115,328
R01 · FY2016 · HL · contact PI
Cardiovascular Regenerative Medicine$2,063,158
P01 · FY2015 · HL · contact PI
PAI-1 & Vascular Senescence$339,331
R01 · FY2015 · HL · contact PI
Cardiovascular Regenerative Medicine$2,106,550
P01 · FY2014 · HL · contact PI
PAI-1 & Vascular Senescence$379,372
R01 · FY2014 · HL · contact PI
Cardiovascular Regenerative Medicine$1,998,615
P01 · FY2013 · HL · contact PI
Cardiovascular Regenerative Medicine$97,191
P01 · FY2013 · HL · contact PI
Cardiovascular Regenerative Medicine$2,156,726
P01 · FY2012 · HL · contact PI
Role of PAI-1 in Cardiovascular Repair and Fibrosis$381,250
P01 · FY2011 · HL · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$370,194
R01 · FY2010 · HL · contact PI
CARDIOVASCULAR CORE$129,218
U24 · FY2010 · DK · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$370,194
R01 · FY2009 · HL · contact PI
CARDIOVASCULAR CORE$129,218
U24 · FY2009 · DK · contact PI
CARDIOVASCULAR CORE$256,569
U24 · FY2008 · DK · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$247,298
R01 · FY2008 · HL · contact PI
PAI-1 and Arterial Thrombosis: Models and Mechanisms$196,772
R01 · FY2008 · HL · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$125,323
R01 · FY2008 · HL · contact PI
PAI-1 and Arterial Thrombosis: Models and Mechanisms$92,069
R01 · FY2008 · HL · contact PI
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY$457
M01 · FY2008 · RR · contact PI
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 IN OBESE POPULATION$223
M01 · FY2008 · RR · contact PI
Cell Therapy for Improving Cardiac Function$554,113
U01 · FY2007 · HL · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$372,419
R01 · FY2007 · HL · contact PI
PAI-1 and Arterial Thrombosis: Models and Mechanisms$291,091
R01 · FY2007 · HL · contact PI
CARDIOVASCULAR CORE$261,788
U24 · FY2007 · DK · contact PI
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY$9,698
M01 · FY2007 · RR · contact PI
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 IN OBESE POPULATION$4,725
M01 · FY2007 · RR · contact PI
SCCOR in Hemostatic and Thrombotic Diseases$3,170,311
P50 · FY2006 · HL · contact PI
Angiotensin, The Vascular Endothelium, and Fibrinolysis$382,083
R01 · FY2006 · HL · contact PI
PAI-1 and Arterial Thrombosis: Models and Mechanisms$298,890
R01 · FY2006 · HL · contact PI
Cardiovascular Mechanisms: Training in Investigation$216,932
T32 · FY2006 · HL · contact PI
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 LEVELS IN AN OBESE POPULATION$4,615
M01 · FY2006 · RR · contact PI
HRT AND PROTEIN EXPRESSION IN POSTMENOPAUSAL WOMEN$1,677
M01 · FY2006 · RR · contact PI
Cardiovascular Mechanisms: Training in Investigation$437,346
T32 · FY2005 · HL
PAI-1 and Arterial Thrombosis: Models and Mechanisms$304,167
R01 · FY2005 · HL
Angiotensin, The Vascular Endothelium, and Fibrinolysis$302,000
R01 · FY2005 · HL
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 LEVELS IN AN OBESE POPULATION$31,317
M01 · FY2005 · RR
Angiotensin, The Vascular Endothelium, and Fibrinolysis$302,000
R01 · FY2004 · HL
MOLECULAR GENETICS OF PAI-1 EXPRESSION$264,250
R01 · FY2004 · HL
Tissue ACE and Fibrinolytic Balance$58,320
M01 · FY2004 · RR
The Effects of Pentoxifylline on PAI-1 Levels in an Obese Population$550
M01 · FY2004 · RR
Angiotensin, The Vascular Endothelium, and Fibrinolysis$302,000
R01 · FY2003 · HL
MOLECULAR GENETICS OF PAI-1 EXPRESSION$264,250
R01 · FY2003 · HL
CARDIOVASCULAR MECHANISMS: TRAINING IN INVESTIGATION$1
T32 · FY2003 · HL
CARDIOVASCULAR MECHANISMS: TRAINING IN INVESTIGATION$428,171
T32 · FY2002 · HL
Angiotensin, The Vascular Endothelium, and Fibrinolysis$302,250
R01 · FY2002 · HL
MOLECULAR GENETICS OF PAI-1 EXPRESSION$264,250
R01 · FY2002 · HL
COMPARATIVE EFFECTS OF RAMIPRIL &LOSARTAN ON FIBRINOLYSIS$0
M01 · FY2002 · RR
QUINAPRIL AND LOSARTAN IN FIBRIOLYTIC BALANCE$0
M01 · FY2002 · RR
ORAL ESTROGEN (PREMARIN) &ACEI (RAMIPRIL) ON FIBRINOLYTIC POTENTIAL$0
M01 · FY2002 · RR
VASCULAR DISEASE IN HBP--ANG II, PAI 1, INSULIN &GENES$0
M01 · FY2002 · RR
CARDIOVASCULAR MECHANISMS: TRAINING IN INVESTIGATION$418,016
T32 · FY2001 · HL
RENIN/ANGIOTENSIN SYSTEM AND FIBRINOLYSIS IN HUMANS$300,743
R01 · FY2001 · HL
MOLECULAR GENETICS OF PAI-1 EXPRESSION$265,052
R01 · FY2001 · HL
QUINAPRIL AND LOSARTAN IN FIBRIOLYTIC BALANCE$0
M01 · FY2001 · RR
QUINAPRIL AND LOSARTAN IN FIBRIOLYTIC BALANCE$0
M01 · FY2001 · RR
ORAL ESTROGEN (PREMARIN) &ACEI (RAMIPRIL) ON FIBRINOLYTIC POTENTIAL$0
M01 · FY2001 · RR
ORAL ESTROGEN (PREMARIN) &ACEI (RAMIPRIL) ON FIBRINOLYTIC POTENTIAL$0
M01 · FY2001 · RR
ORAL ESTROGEN (PREMARIN) &ACEI (RAMIPRIL) ON FIBRINOLYTIC POTENTIAL$0
M01 · FY2001 · RR
COMPARATIVE EFFECTS OF RAMIPRIL &LOSARTAN ON FIBRINOLYSIS$0
M01 · FY2001 · RR
COMPARATIVE EFFECTS OF RAMIPRIL &LOSARTAN ON FIBRINOLYSIS$0
M01 · FY2001 · RR
COMPARATIVE EFFECTS OF RAMIPRIL &LOSARTAN ON FIBRINOLYSIS$0
M01 · FY2001 · RR
VASCULAR DISEASE IN HBP--ANG II, PAI 1, INSULIN &GENES$0
M01 · FY2001 · RR
VASCULAR DISEASE IN HBP--ANG II, PAI 1, INSULIN &GENES$0
M01 · FY2001 · RR
VASCULAR DISEASE IN HBP--ANG II, PAI 1, INSULIN &GENES$0
M01 · FY2001 · RR
QUINAPRIL AND LOSARTAN IN FIBRIOLYTIC BALANCE$0
M01 · FY2001 · RR
CARDIOVASCULAR MECHANISMS: TRAINING IN INVESTIGATION$398,982
T32 · FY2000 · HL
RENIN/ANGIOTENSIN SYSTEM AND FIBRINOLYSIS IN HUMANS$293,334
R01 · FY2000 · HL
MOLECULAR GENETICS OF PAI-1 EXPRESSION$265,125
R01 · FY2000 · HL
ANGIOTENSIN, THE VASCULAR ENDOTHELIUM AND FIBRINOLYSIS$258,759
R01 · FY2000 · HL
COMPARATIVE EFFECTS OF RAMIPRIL &LOSARTAN ON FIBRINOLYSIS$592
M01 · FY2000 · RR
VASCULAR DISEASE IN HBP--ANG II, PAI 1, INSULIN &GENES$592
M01 · FY2000 · RR
ORAL ESTROGEN (PREMARIN) &ACEI (RAMIPRIL) ON FIBRINOLYTIC POTENTIAL$0
M01 · FY2000 · RR
QUINAPRIL AND LOSARTAN IN FIBRIOLYTIC BALANCE$0
M01 · FY2000 · RR